Clinical trial NCT03346070 - References

Neuromuscular Blockade — Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

Citation(s)

•   Mostoller K, Wrishko R, Maganti L, Herring WJ, van Zutphen-van Geffen M
  Pharmacokinetics of Sugammadex Dosed by Actual and Ideal Body Weight in Patients With Morbid Obesity Undergoing Surgery. Clin Transl Sci. 2020 Dec 5. doi: 10.1111/cts.12941. [Epub ahead of print]

A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in Morbidly Obese Subjects

Details for clinical trial NCT03346070